Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) recently initiated a phase I multiple dose study with APD811, which is being developed for the treatment of pulmonary arterial hypertension (PAH).

Arena Pharma is expecting to enroll 30 healthy adult volunteers for this randomized, double-blind and placebo-controlled dose titration trial. The trial will study the safety, tolerability and pharmacokinetics of the candidate.

We note that the PAH market already has players like Gilead Sciences Inc. (GILD - Analyst Report), GlaxoSmithKline plc (GSK - Analyst Report), Actelion Ltd. (ALIOF) and United Therapeutics Corporation (UTHR - Analyst Report).

Meanwhile, Arena Pharma achieved a major milestone in June this year when the US Food and Drug Administration (FDA) approved Belviq as an adjunct to a healthy diet (low on calories) and increased physical activity for chronic weight management in obese (Body Mass Index, or BMI, ≥30) or overweight (BMI ≥27) adults suffering from at least one weight-related co-morbid condition. The move marks the first FDA approval for a weight-loss drug in 13 years.

The safety and efficacy of Belviq when co-administered with other weight loss products and the effect on cardiovascular morbidity and mortality are yet to be established. Hence, the FDA recommended Belviq to be classified by the US Drug Enforcement Administration (DEA) as a scheduled drug.

Belviq is currently under review in the EU and the company has filed a marketing application in Switzerland. Arena Pharma and Eisai have a partnership agreement for Belviq.

Our Recommendation

We currently have a Neutral recommendation on Arena Pharma. The stock carries a Zacks #3 Rank (short-term Hold rating).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDST ENLC 36.29 +1.60%
BNC BANCORP BNCN 17.33 +1.58%